|
FDA Warning to Hospira Infusion Plant May Hint at Broader Problems
An FDA warning letter issued to Hospira’s infusion pump plant in Costa Rica may be emblematic of broader companywide manufacturing issues, analysts say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives